- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
13 result(s) found for: Prenatal period.
Displaying page 1 of 1.
EudraCT Number: 2015-003699-60 | Sponsor Protocol Number: KIBB01 | Start Date*: 2018-09-28 |
Sponsor Name:Karolinska Institutet | ||
Full Title: An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal intravenous administration of allogeneic expanded fetal... | ||
Medical condition: Treatment of Osteogenesis Imperfecta (OI) type III and severe type IV. | ||
Disease: | ||
Population Age: In utero, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003181-12 | Sponsor Protocol Number: HOTPOT1 | Start Date*: 2016-10-07 |
Sponsor Name:Royal College of Surgeons in Ireland | ||
Full Title: Can sonographic assessment of pulmonary vascular reactivity following maternal hyperoxygenation therapy predict neonatal outcome in fetuses at risk of pulmonary hypertension? | ||
Medical condition: Persistent pulmonary hypertension of the newborn (PPHN) is a relatively common condition occurring in 7/1000 births and can result in significant cardiovascular instability in the newborn. It occur... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-002702-30 | Sponsor Protocol Number: ALXN1101-MCD-202 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Origin Biosciences, Inc. | |||||||||||||
Full Title: A PHASE 2/3, MULTICENTER, MULTINATIONAL, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALXN1101 IN NEONATES WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A | |||||||||||||
Medical condition: Molydenum CoFactor Deficiency (MoCD) Type A | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) IT (Prematurely Ended) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002430-36 | Sponsor Protocol Number: AntibioTICS | Start Date*: 2012-07-02 | |||||||||||
Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | |||||||||||||
Full Title: Multicentre, randomised, double-blinded, placebo-controlled trial of efficacy of amoxicilline/clavulanic acid in patients affected by tic disorder colonized by GAS. No-proft stidy. | |||||||||||||
Medical condition: Chronic tic disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) ES (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003325-10 | Sponsor Protocol Number: 1.01 | Start Date*: 2012-08-10 | |||||||||||||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||||||||||||
Full Title: A randomized controlled trail on the effects of periconceptional and prenatal folic acid supplementation on congenital anomalies and preterm birth | |||||||||||||||||||||||
Medical condition: congenital anomalies | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000649-30 | Sponsor Protocol Number: P150905 | Start Date*: 2016-09-29 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Impact of the administration of Fludrocortisone the fluid and electrolyte balance in great premature. Pilot study. | |||||||||||||
Medical condition: Great prematurity | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006766-21 | Sponsor Protocol Number: MINI-SPIOMET | Start Date*: 2022-09-02 | |||||||||||
Sponsor Name:Hospital de Girona Dr. Josep Trueta | |||||||||||||
Full Title: Towards a treatment for accelerated maturation in girls testing spiomet in a randomised placebo controlled, multicentre study. | |||||||||||||
Medical condition: Girls with advanced puberty and accelerated bone maturation. Polycystic Ovary Syndrome (PCOS) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000062-14 | Sponsor Protocol Number: MN42988 | Start Date*: 2021-10-08 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A PHASE IV MULTICENTER, OPEN-LABEL STUDY EVALUATING B CELL LEVELS IN INFANTS POTENTIALLY EXPOSED TO OCRELIZUMAB DURING PREGNANCY – THE MINORE STUDY | ||||||||||||||||||
Medical condition: Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS) [in line with the locally approved indications] | ||||||||||||||||||
|
||||||||||||||||||
Population Age: In utero, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) DE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003326-41 | Sponsor Protocol Number: 200719 | Start Date*: 2016-01-13 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: Randomized, Double-Blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Placebo for Women in Spontaneous Preterm Labor | |||||||||||||
Medical condition: Preterm Labour | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000770-29 | Sponsor Protocol Number: Ireland-RctV8 | Start Date*: 2018-06-18 | ||||||||||||||||
Sponsor Name:The Rotunda Hospital | ||||||||||||||||||
Full Title: Investigating the role of early low-dose aspirin in diabetes: A phase III multicentre double-blinded placebo-controlled randomised trial of low-dose aspirin initiated in the first trimester of diab... | ||||||||||||||||||
Medical condition: Pregestational type I or type II diabetes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: IE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-001826-13 | Sponsor Protocol Number: 200721 | Start Date*: 2015-02-16 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban Therapy for Women in Spontaneous Preterm Labor | |||||||||||||
Medical condition: preterm labor | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) SE (Completed) ES (Completed) DE (Completed) IT (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001119-38 | Sponsor Protocol Number: 116945 | Start Date*: 2015-09-21 | |||||||||||||||||||||
Sponsor Name:GlaxoSmithKline | |||||||||||||||||||||||
Full Title: A Phase IV, observer-blind, randomised, cross-over, placebo-controlled, multicentre study to assess the immunogenicity and safety of a single dose of Boostrix? in pregnant women. | |||||||||||||||||||||||
Medical condition: Booster immunisation against diphtheria, tetanus and pertussis diseases. The study population for this study will include pregnant women. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||
Trial protocol: ES (Completed) CZ (Completed) FI (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-015953-18 | Sponsor Protocol Number: DORIPED3002 | Start Date*: 2010-05-28 | |||||||||||
Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium | |||||||||||||
Full Title: A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infec... | |||||||||||||
Medical condition: Complicated Urinary Tract Infections | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) CZ (Completed) PL (Temporarily Halted) LV (Prematurely Ended) DE (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
